Insights

View our latest blog posts, webinars and news stories below

Digital Health Leader Joins Leavitt Partners

Leavitt Partners, an HMA Company, is pleased to announce that Mark Marciante has joined the company’s digital health team of experts. He will be a director located in the company’s Washington, D.C., office. Marciante has extensive experience in digital health, successfully driving transformative initiatives for healthcare payers over the past decade. As director of engineering … Continue reading

New Report: Analyzing the Expanded Landscape of Value-Based Entities – Implications and Opportunities of Enablers for the CMS Innovation Center and the Broader Value Movement

New Report Analyzes the Expanding Landscape of Value-Based Entities     Research from HMA and LP VBP experts segments and sizes the growing enabler market, considering benefits and risks, and proposing guiding principles and policy recommendations for the CMS Innovation Center A new in-depth HMA report analyzes the landscape of emerging value-based entities and the implications … Continue reading

Political Checkpoint on Healthcare Policy in 2024

The 2024 election cycle will dominate the headlines, but there will be meaningful health policy both in Congress and in the Biden Administration. This year the Leavitt Partners Political Checkpoint is a video featuring Governor Michael Leavitt and members of our D.C. team talking about short term and longer term outlook on major issues and the … Continue reading

New White Paper: A Vision for the Future of Medicare Advantage Supplemental Benefits: Advancing Value, But Validating Results

Medicare Advantage plans in the United States continue to explode in popularity, now reaching over 30 million Americans, due to the broad appeal of supplemental benefits that can be offered by plans to enrollees. What started off as a core set of benefit offerings, including dental, vision, and over-the-counter medications, has recently been expanded by … Continue reading

New Task Force Endorses Legislation to Save Rare Disease Treatments 

The Save Rare Treatments Task Force, a new multi-sector public policy and advocacy collaboration convened by Leavitt Partners, an HMA Company, publicly launched this week and today released a letter of support for recently introduced, bipartisan, bicameral legislation. The Task Force is comprised of organizations representing persons living with rare diseases, biopharmaceutical innovators, and other … Continue reading

A Vision for Consumer Engagement in Health 

Rebecca Nielsen, Managing Director, Leavitt Partners, an HMA CompanySpencer Morrison, Associate Principal, Leavitt Partners, an HMA Company  PillPack boasts the tagline, “Pharmacy Simplified.” The mail-order pharmacy successfully streamlined the activities associated with managing medications. It illuminated for its customers what medications they needed to take next, and at what time, by packaging meds in a … Continue reading

New White Paper: “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward”

In “Aggregated Precision Investment: Strengths, Weaknesses, and Potential Paths Forward,” Rebecca Nielsen, Brooke Zollinger, and Sarah Johnson from Leavitt Partners explore the feasibility of operationalizing an aggregated precision investment (API) model for social determinants of health (SDOH) interventions. The authors derive their findings from subject matter expert interviews, conversations with potential aggregators, and relevant secondary research. This article enumerates … Continue reading

New white paper from Medicines Development Modernization Initiative

Data science and digital health in clinical development and operations: impact, challenges, and calls to action for the drug development ecosystem In this paper, the Medicines Development Modernization Initiative discuss how three medicines development tools (MDTs) – artificial intelligence (AI) and machine learning (ML) algorithms, digital health tools (DHTs), and augmentation of randomized controlled trial … Continue reading